Business Wire

MUSE

20.10.2021 15:02:13 CEST | Business Wire | Press release

Share
Interaxon Inc. (Muse®) Launches the Latest in Non-Pharmaceutical Sleep Support: EEG-Powered ‘Digital Sleeping Pills’ That Provide Immediate & Intelligent Support for Falling Asleep & Nighttime Interruptions

Interaxon Inc. (Muse® ), a leading consumer neurotechnology and meditation company, today announced the launch of the second generation of its popular EEG meditation & sleep headband, Muse S. This updated plush brain-sensing headband uses real-time biofeedback to help you learn the art of mediation as well as help you fall asleep, stay asleep and now go back to sleep if you awaken during the night.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005215/en/

Alongside the launch of the updated Muse S headband, Interaxon is launching an intelligent new kind of EEG-powered sleep experience that is designed to help put you to sleep and guide you back to sleep if you’ve woken during the night.

Interaxon has been excited to offer this never-before-seen sleep intervention after building on their successful release of sleep content & EEG sleep tracking insights to support healthy sleep habits. A recent 2021 study led by Western University, Cambridge Brain Science, Hatch, and Interaxon that used Muse S EEG-sleep support technology showed a 20% improvement in the Pittsburgh Sleep Quality Index, relative to controls wanting to improve their sleep.

“For many of us, increasingly busy days translate into busy minds at night and restless sleep. While sleep tracking can be helpful to gain insights on trends and changes in your sleep quality, tracking your sleep doesn’t provide immediate relief when you need it most,” said Walter Greenleaf, Chief Science Officer at Interaxon (Muse®). “According to the CDC, more than a third of American adults are not getting enough sleep on a regular basis with less than seven hours per day.1 This innovative new solution can help users get the rest they need to improve their overall wellness with a non-pharmaceutical sleep aid.”

Digital Sleeping Pills (DSPs)

Muse Digital Sleeping Pills or DSPs are designed to help you through the wind-down process by responding to your brain’s rhythms and helping you disengage from your busy mind. Muse S detects the natural changes in your brain activity as you fall asleep and uses those changes to gently fade out your audio to cue your brain that it’s time for sleep. If you wake in the night, Muse S uses the same Smart-Fade technology to automatically fade in the DSP content to guide you back to sleep again.

Sleep content preferences can vary widely from person to person. Some people are looking for a more engaging story to keep their mind from getting stuck in ruminating thoughts, while others may find a story too exciting to fall asleep to and prefer a softer, guided meditation or ambient soundscape. Depending on what type of content helps you fall asleep best, you can select a variety of different DSP’s to help you on your journey including all-new:

  • Original, Classic, and Adventure Sleep Stories that have a voice narration of some of your favorite childhood stories & a variety of new original stories
  • Ambient Sleep Soundscapes that offer soothing ambient music and harmonized sounds without a voice narrative
  • Biofeedback Sleep Soundscapes that offer nature sounds and music that respond to biofeedback without a voice narrative
  • Guided Sleep Meditations that have a meditation teacher guide you through a relaxing sleep meditation

In addition to the advanced EEG technology that Muse® is known for, the all-new second-generation Muse® S has improved signal quality for increased accuracy and enhanced battery performance with up to 50% reduction in charging time. Additionally, improved fit for a wider range of head sizes has been achieved with the same comfortable, adjustable, and washable fabric band.

Pricing and Availability

Muse® S (Gen 2) is now available for $399.99 USD at www.choosemuse.com and will be available on Amazon North America starting in 2022. Both first and second-generation Muse® S headbands will have access to the new Digital Sleep Pill (DSP) features free of charge with Gen 1 users gaining access in December of 2021.

To unlock Biofeedback+ and unlimited access to 500+ meditations with new content released monthly, you can subscribe to the Muse Premium Subscription for $12.99 USD per month or $94.99 USD per year.

In addition to a rich content library of more than 500 meditations from renowned meditation teachers, unlock access to a variety of relaxation techniques, Go-to-Sleep soundscapes, and in-depth courses with step-by-step instructions, such as The Sleep Basics course by Dr. Shelby Harris, an expert in behavioral sleep medicine. Additionally, you’ll have access to Biofeedback+ which is designed to allow you to see how your brain and body responds to external content whether it be music in Spotify, Audiobooks, or meditations in Headspace.

Now available at www.choosemuse.com .

About Muse ® by Interaxon Inc. :

At Muse®, our team of neuroscientists, meditation teachers, and engineers based out of Toronto who develop state-of-the-art experiences using research-grade EEG technology. Our goal is to help individuals build a rewarding meditation practice and live healthier, happier, more connected lives through human-centered technology. Our award-winning neurofeedback devices, and premium content offering of guided meditations with responsive learning functionality, is designed to help users meditate by providing real-time audio feedback on their meditative state through the Muse® companion app. We make the intangible, tangible. Muse is headquartered in Toronto, Canada, and has subsidiaries in the U.S. and Ireland.

More information about Muse® is available at www.choosemuse.com .

Milestones we’re excited about:

  • More than 500,000 Musers globally
  • Accessible: Muse is available in four languages, including English, Spanish, French and German
  • Sessions of meditation with Muse ®: Over 100 million minutes to date and currently one of the largest brain data (EEG) collections in the world.
  • Research institutions using Muse®: The Mayo Clinic, NASA, Harvard, MIT, U of T, UCL, UCSD, Inria, UVic, UBC, and many more.
  • Meditating with Muse® works: Muse has been used in over 200 published studies, including Mayo Clinic who demonstrated meditating with Muse increases quality of life, and decreases stress and fatigue in cancer patients.
  • Untangle Podcast : With more than 7 million plays, Untangle hosts Patricia Karpas and Ariel Garten interview thought-provoking authors, experts and leaders in areas related to mindfulness, sleep, neuroscience, brain health practices, and more.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye